Terflavoxate is a benzopyran derivative patented by Recordati S. A. Chemical and Pharmaceutical Co. as a muscle relaxant, anesthetic, anti-inflammatory, and antispastic agent useful for the treatment of lower urinary tract disease. Terflavoxate inhibited by more than 50% field stimulation-induced contractions of rabbit bladder strips, indicates that mechanisms other than the anticholinergic one should be responsible for its smooth muscle relaxant properties.

Terciprazine was developed as an antihypertensive agent that has never been marketed. Information about the current use of this drug is not available.

Flamenol (3,5-Dihydroxyanisole) is organic compound used in synthesis of isorobustin and substituted linear and angular benzofurocoumarins

FLEROBUTEROL is a beta-adrenoceptor agonist with potential antidepressant activity.

Succisulfone is a sulfonamide derivative patented by Antoine Mouneyrat as antibiotic useful in the treatment of leprosy

Tiotidine is a controversial histamine H2 receptor ligand with negligible activity against H1- and H3- receptors. It was found that tiotidine behaves as an inverse agonist in U-937 cells, diminishing basal cAMP levels. Tiotidine showed two binding sites, one with high affinity and low capacity and the other with low affinity and high capacity. Tiotidine is currently in use as a radioligand in histamine H2-receptor binding studies. Compared to cimetidine, tiotidine appears to be approximately eight times more potent on a molar basis than cimetidine as an inhibitor of acid secretion, and the tiotidine effect is more prolonged. It was developed for the treatment of peptic ulcer.

Gapicomine is a coronary vasodilator, developed in Poland. It has been withdrawn from the market in the countries it was used in. Gapicomine is a major component in the drug Bicordin.

Pendecamaine, a zwitterionic agent that was used as an ampholytic surface-active agent in surgical scrubs and in cosmetic and toilet preparations. Information about the current use of this drug is not available.

Phthalylsulfamethizole is the sulfonamide. It was used as an antibacterial agent.

Sonepiprazole exhibits highly specific binding to the D4 dopamine receptor with more than 100-fold selectivity for the D4 receptor over other receptors, including dopamine, serotonin, and adrenergic receptors. It is a neutral antagonist at the D4 dopamine receptor and is devoid of dopamine agonist activity. Sonepiprazole selectively induces c-fos expression in the prefrontal cortex and blocks behavioral, biochemical, and genomic effects of repeated amphetamine administration in rats. Sonepiprazole was investigated as an antipsychotic for the treatment of schizophrenia in a placebo-controlled clinical trial, but in contrast to its comparator olanzapine no benefits were found and it was not researched further for this indication.